UNSPSC 51361704: Zaleplon

This classification denotes a sedative and hypnotic with the molecular formula C17H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S62U433RMH, chemically known as 3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide but generally known as zaleplon, which bears US NIH Compound Identifier 5719. European Medicines Agency schedules Zaleplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00132MIG. The term ZALEPLON is an International Non-Proprietary Name.

UNSPSC 51361704 Zaleplon is a Commodity code that represents pharmaceutical products—specifically zaleplon, a sedative-hypnotic medication—but recent state and local procurement activity under this code shows little direct alignment with zaleplon itself. Instead, the opportunities posted against this code reflect broader pharmaceutical and health-related procurement, including naloxone (an opioid antagonist), over-the-counter drugs, generic pharmaceuticals, and direct-to-manufacturer pharmacy programs. State and local governments are using this code to source pharmaceuticals through a mix of issuing bodies: individual counties (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple states including Oregon). The scope spans emergency-response medications like naloxone, generic multi-source drugs distributed through authorized pharmaceutical wholesalers, and exploratory pharmacy benefit programs designed to establish direct relationships between state agencies and manufacturers.

Recent opportunities show activity concentrated in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the county's community health building and a response deadline of July 26, 2023 (note: the due date appears inconsistent with the posted date and may reflect a data error in the source). The Texas Health and Human Services Commission issued Request for Information HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, intended to inform future formal solicitation. MMCAP, administered by Minnesota's Department of Administration, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with responses due March 26, 2026 and awards effective July 1, 2026. Vendors must hold current Good Manufacturing Practices and Drug Supply Chain Security Act certifications, maintain relationships with designated wholesalers, and carry substantial commercial general liability ($5 million per occurrence) and network security and privacy liability ($2 million).